Eli Lilly and Co
LLY896.750USD
+11.549+1.30%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
849.70BMarket Cap
80.24P/E TTM
More Details of Eli Lilly and Co Company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule FXR314.
Company Info
Company codeLLY
Company nameEli Lilly and Co
IPO dateJul 09, 1970
Founded at1901
CEOMr. David A. (Dave) Ricks
Number of employees47000
Security typeOrdinary Share
Fiscal year-endJul 09
AddressLilly Corporate Ctr
CityINDIANAPOLIS
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code46285
Phone13172762000
Websitehttps://www.lilly.com/
Company codeLLY
IPO dateJul 09, 1970
Founded at1901
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.71K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.97K
+26.18%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President - Human Resources and Diversity
Executive Vice President - Human Resources and Diversity
9.84K
+15.72%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
72.71K
+0.02%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
43.54K
+175.92%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.75K
+4.13%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
28.76K
+45.24%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
By RegionUSD
Name
Revenue
Proportion
U.S.
30.38B
67.44%
Europe
6.92B
15.36%
Other foreign countries
4.27B
9.48%
Japan
1.81B
4.03%
China
1.66B
3.69%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
11.54B
25.62%
Oncology-Verzenio
5.31B
11.78%
Diabetes-Trulicity
5.25B
11.66%
Diabetes-Zepbound
4.93B
10.94%
Diabetes-Jardiance
3.34B
7.42%
Other
14.68B
32.58%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Shareholder Statistics
Shareholder
Proportion
Lilly Endowment, Inc.
10.13%
The Vanguard Group, Inc.
7.80%
PNC Investments LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.62%
Other
68.73%
Type
Shareholder
Proportion
Investment Advisor
38.03%
Investment Advisor/Hedge Fund
25.86%
Foundation
10.13%
Research Firm
1.89%
Pension Fund
1.88%
Bank and Trust
1.79%
Insurance Company
1.43%
Sovereign Wealth Fund
1.24%
Hedge Fund
1.10%
Other
16.65%
Institutional Shareholding
Update time: Thu, Feb 20
Update time: Thu, Feb 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
5592
794.50M
83.80%
+1.17M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
2022Q4
3985
805.64M
84.79%
-7.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 03, 2025
The Vanguard Group, Inc.
73.90M
7.8%
+486.78K
+0.66%
Dec 31, 2024
PNC Investments LLC
51.08M
5.39%
-49.68K
-0.10%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
41.11M
4.34%
+29.75K
+0.07%
Dec 31, 2024
State Street Global Advisors (US)
34.31M
3.62%
+461.69K
+1.36%
Dec 31, 2024
Fidelity Management & Research Company LLC
29.35M
3.1%
-2.42M
-7.60%
Dec 31, 2024
T. Rowe Price Associates, Inc.
19.73M
2.08%
-77.25K
-0.39%
Dec 31, 2024
Capital World Investors
19.55M
2.06%
-803.44K
-3.95%
Dec 31, 2024
Geode Capital Management, L.L.C.
17.38M
1.83%
+291.88K
+1.71%
Dec 31, 2024
PRIMECAP Management Company
16.76M
1.77%
-933.85K
-5.28%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Defiance Daily Target 2X Long LLY ETF
30.83%
iShares U.S. Pharmaceuticals ETF
21.6%
Amplify Weight Loss Drug & Treatment ETF
18.44%
Roundhill GLP-1 & Weight Loss ETF
18.11%
VanEck Pharmaceutical ETF
12.4%
Proshares Ultra Health Care
12.21%
Health Care Select Sector SPDR Fund
11.98%
iShares U.S. Healthcare ETF
11.95%
Fidelity MSCI Health Care Index ETF
11.93%
Simplify Health Care ETF
11.07%
View more
Defiance Daily Target 2X Long LLY ETF
Proportion30.83%
iShares U.S. Pharmaceuticals ETF
Proportion21.6%
Amplify Weight Loss Drug & Treatment ETF
Proportion18.44%
Roundhill GLP-1 & Weight Loss ETF
Proportion18.11%
VanEck Pharmaceutical ETF
Proportion12.4%
Proshares Ultra Health Care
Proportion12.21%
Health Care Select Sector SPDR Fund
Proportion11.98%
iShares U.S. Healthcare ETF
Proportion11.95%
Fidelity MSCI Health Care Index ETF
Proportion11.93%
Simplify Health Care ETF
Proportion11.07%
Dividend
A total of
18.06B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data